论文部分内容阅读
Objective:To prospectively evaluate the efficacy of Cernilton for benign prostatic hyperplasia (BPH) with histological prostatitis after transurethral resection of the prostate (TURP).Materials and methods:One hundred patients with histological prostatitis were recruited from January 2007 to January 2013.All the patients were divided into group A(mild), B(moderate) and C(severe), and they were randomized into a trial group and a control group.The trial group was treated with Cernilton for three months after TURP, while the control group received placebo.We evaluated the indicators before,peri, and after TURP.Results: There were no significant differences in the indicators before and peri TURP.In six months after TURP, there were no differences in all the indicators in group A, there were differences in Erectile Function-5 (IIEF-5) in group B, there were differences in storage symptom score (Ss), patient quality of life (QoL),and International Index of IEFF-5 in group C.In all the patients, there were significant differences in Ss, QoL, and IEFF-5 between the trial and control group.Conclusions:As to BPH patients with histological prostatitis after TURP,administration of Cernilton can improve LUTS and sexual disfunction with the different grades.